EGRX — Eagle Pharmaceuticals Share News
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
- $12.99m
- $67.83m
- $316.61m
Brief: Eagle Pharmaceuticals Outlook FY Adjusted EPS USD 4.4-4.7
Brief: Eagle Pharmaceuticals Announces First Patient Randomized In Phase 2 Study Evaluating CAL02 In Severe Community-Acquired Bacterial Pneumonia
Brief: Eagle Pharmaceuticals Announced Resumption Of Repurchases Of Common Stock On Open Market
Brief: Eagle Pharmaceuticals Provides Business Update And Reiterates 2023 Guidance
Brief: Eagle Pharmaceuticals Receives FDA Qualified Infectious Disease Product (QIDP)
Brief: Eagle Pharmaceuticals Delivers Notice Of Termination Of License Deal To AOP
Eagle Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary
Brief: Eagle Pharmaceuticals Q1 revenue USD 66.3 million
Brief: Eagle Pharmaceuticals Reports First Quarter 2023 Results
Eagle Pharmaceuticals Inc expected to post earnings of $1.05 a share - Earnings Preview
Brief: Eagle Pharmaceuticals Granted Unique J-Code For Byfavo (Remimazolam For Injection) From CMS
Brief: Eagle Pharmaceuticals Reaches Settlement With Dr. Reddy's Laboratories Inc, Dr. Reddy's Laboratories Ltd Related To Bendeka (Bendamustine Hydrochloride)
Brief: Eagle Pharmaceuticals Files Non-Timely 10-K With US SEC
U.S. RESEARCH ROUNDUP-Ncino, Newmont, Seagen
Eagle Pharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary
Brief: Eagle Pharmaceuticals Reports Q4 Adjusted EPS Of $1.10
Brief: Eagle Pharmaceuticals reports Q4 revenue of USD 60.7 million
Eagle Pharmaceuticals Inc expected to post earnings of 83 cents a share - Earnings Preview
Eagle Pharmaceuticals Inc expected to post earnings of 83 cents a share - Earnings Preview